Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Exclusion Criteria

• •1. Participants with small-cell lung cancer or mixed small-cell lung cancer
• •2. Participants who require or may require pneumonectomy
• •3. Prior treatment with programmed cell death ligand-1 (PD-L1), PD-L1, or cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors
• •4. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug.
• •5. Active or prior documented autoimmune or inflammatory disorders. The following are exceptions to this criterion:
• •1. Participants with vitiligo or alopecia
• •2. Participants with hypothyroidism on hormone replacement
• •3. Any chronic skin condition that does not require systemic therapy
• •4. Participants without active disease in the last 5 years may be included but only after consultation with the study physician
• •5. Participants with celiac disease controlled by diet alone
• •6. Pregnant or breast-feeding female
• •7. Major surgical procedure within prior 30 days
• •8. History of active primary immunodeficiency
• •9. Active infection including tuberculosis, hepatitis B, hepatitis C, or HIV
• •10. QTc interval (QTc) ≥ 470 ms
• •11. Uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the participant to give written informed consent
• •12. Receipt of live attenuated vaccination within 30 days prior to study entry
• •13. History of another primary malignancy except for:
• •1. Curative-treated malignancy with no known active disease \> 2 years before enrollment on the study
• •2. Curative-treated non-melanoma skin cancer and/or carcinoma in-situ